# Moderna Stock Hype Over Cancer Vaccine

> Moderna's cancer vaccine stock price far exceeds fair value, demanding Keytruda-scale success.
- Title: Moderna Stock Hype Over Cancer Vaccine · Seekingalpha
- Summary: Moderna's cancer vaccine stock price far exceeds fair value, demanding Keytruda-scale success. Moderna's stock price is priced at $69B peak sales for…
- Keywords: moderna, intismeran, keytruda, cancer vaccine, stock price, phase 3, money, business, Stock, Hype, Cancer, Vaccine
- Source: Seekingalpha — https://seekingalpha.com/article/4955490-moderna-sell-the-cancer-vaccine-hype
- Author: Justin Miller
- Published: 2026-10-20T14:14:53+00:00
- Read time: 1 min
- Topics: moderna, intismeran, keytruda, cancer vaccine, stock price, phase 3, money, business
## Moderna Stock Rating
Moderna is rated Sell as the stock price far exceeds even the most bullish fair value estimates.
## Valuation Implications
MRNA's valuation implies $69B in peak sales for intismeran despite the company only owning half.
## Timeline for Approval
First approval for intismeran is unlikely before 2027.
## Market Expectations
The market is pricing in a perfect outcome yet pivotal Phase 3 hazard ratio data remains undisclosed.
## Key takeaway

Moderna's stock price is priced at $69B peak sales for intismeran despite first approval unlikely before 2027.